Gilead buys YM for $510m

By Andrew Turley2012-12-20T00:00:00+00:00

No comments

Deal gives Gilead access to Janus kinase inhibitor CYT387 for the treatment of myelofibrosis

US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million (£310 million).

The lead drug candidate at YM is CYT387, a selective inhibitor of the Janus kinase (JAK) enzymes, which are thought to be involved in several of disorders, including myeloproliferative diseases, inflammatory disorders and certain types of cancer.

Gilead is planning a Phase III trial of CYT387 against myelofibrosis in the second half of 2013.

YM gained CYT387 when it bought Australian biotech Cytopia in 2009.

References

Topics

No comments

Opinion
Two heads are better than one
2020-02-19T14:27:00Z
Bifunctionals show that sometimes simply tethering two useful molecules together unlocks some useful activity
Business
Solar-powered water purification
2020-02-19T09:28:00Z
Majico’s photocatalytic water kiosks are increasing access to affordable drinking water in Tanzania
News
Number of industrial chemicals being produced globally grossly underestimated
2020-02-18T14:30:00Z
Analysis of national chemical inventories finds three times as many chemicals registered for production as previously thought